Giusy Di Conza

6PUBLICATIONS
73CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Innate immunity
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Oct 08, 2026
Roginolisib in Combination with JAK Inhibitors in Patients with Myelofibrosis Who are Unresponsive to Approved JAK Inhibitors (Study HEMA-MED) - A Trial in Progress.

|Jan 22, 2026
The PI3Kδ inhibitor roginolisib (IOA-244) preserves T-cell function and activity.

Elise Solli, Alessio Bevilacqua, Mathias Wenes

|Nov 21, 2024
Pancreatic CAF-Derived Autotaxin Drives Autocrine CTGF Expression to Modulate Protumorigenic Signaling.

Fanny Volat, Ragini Medhi, Lauren Z Maggs

|Sep 22, 2023
Autotaxin Secretion Is a Stromal Mechanism of Adaptive Resistance to TGFβ Inhibition in Pancreatic Ductal Adenocarcinoma.

Silvia Pietrobono, Fabio Sabbadini, Monica Bertolini

|Apr 17, 2023
IOA-244 is a Non-ATP-competitive, Highly Selective, Tolerable PI3K Delta Inhibitor That Targets Solid Tumors and Breaks Immune Tolerance.

Zoë Johnson, Chiara Tarantelli, Elisa Civanelli

|Feb 09, 2023
Control of immune cell function by the unfolded protein response.

Giusy Di Conza, Ping-Chih Ho, Juan R Cubillos-Ruiz

Pageof 1

Frequent Collaborators

3 joint publications

Michael Lahn

2 joint publications

Zoë Johnson

2 joint publications

Lars van der Veen

2 joint publications

Amy Fraser